Olon Group, a global producer of active pharmaceutical ingredients, has acquired biotech CDMO GTP Bioways Group.
The acquisiton of GTP Bioways, a French company specialising in the development and production of monoclonal antibodies (mAbs), proteins, enzymes, antibody-drug conjugates and nanodrugs, will allow Olon’s biotech division to diversify its technology offerings, while also supporting customers end-to-end through the biotherapeutic development process.
Acquisition to boost Olon's biotech offerings
GTP Bioways operates out of four sites situated across France which focus on development, clinical trials and cGMP manufacturing.
The company focuses on ADC manufacturing through microbial and mammalian fermentation, nanodrug manufacturing, fill/finish and analytics — including immuno assays.
It also hosts expertise in bioconjugation, which can assist customers especially through the pre-clinical phases, as well as early clinical studies.
“The acquisition of GTP Bioways Group implies a strong and significant strengthening of Olon's service pipeline with the aim of creating new business opportunities, acquiring new customers and high-potential market areas, and ultimately continuing the company's growth,” stated Paolo Tubertini, CEO of the Olon Group.
[Photo credit: Olon Group]
